AstraZeneca PLC Stock price

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 12:35:12 2024-03-18 pm EDT 5-day change 1st Jan Change
10,290 GBX -0.04% Intraday chart for AstraZeneca PLC -1.53% -2.92%
Sales 2024 * 51.01B Sales 2025 * 54.59B Capitalization 203B
Net income 2024 * 8.98B Net income 2025 * 10.26B EV / Sales 2024 * 4.34 x
Net Debt 2024 * 18.42B Net Debt 2025 * 12.07B EV / Sales 2025 * 3.94 x
P/E ratio 2024 *
23 x
P/E ratio 2025 *
20.1 x
Employees 89,900
Yield 2024 *
2.37%
Yield 2025 *
2.48%
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.04%
1 week-1.53%
Current month+3.08%
1 month+1.94%
3 months-0.64%
6 months-4.08%
Current year-2.92%
More quotes
1 week
10 240.00
Extreme 10240
10 516.00
1 month
9 822.00
Extreme 9822
10 534.00
Current year
9 461.00
Extreme 9461
11 022.00
1 year
9 461.00
Extreme 9461
12 392.00
3 years
7 045.00
Extreme 7045
12 392.00
5 years
5 626.00
Extreme 5626
12 392.00
10 years
3 680.00
Extreme 3680
12 392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 12-09-30
Director of Finance/CFO 50 21-07-31
Chief Tech/Sci/R&D Officer 56 19-12-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Corporate Officer/Principal 59 13-01-31
Director/Board Member 63 17-04-26
More insiders
Date Price Change Volume
24-03-18 10,290 -0.04% 3,782,068
24-03-15 10,294 -1.04% 5,253,583
24-03-14 10,402 -0.54% 2,846,633
24-03-13 10,458 +0.21% 4,183,232
24-03-12 10,436 -0.13% 3,246,478

Delayed Quote London S.E., March 18, 2024 at 12:35 pm EDT

More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
130.9 USD
Average target price
161.1 USD
Spread / Average Target
+23.05%
Consensus
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.